B+
Bull case
0%
Probability
Target price
$12.50
+52.3% vs current
EBS
Emergent BioSolutionsCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
0%
Probability
Target price
$9.50
+15.7% vs current
B-
Bear case
0%
Probability
Target price
$6.00
-26.9% vs current
AI sentiment snapshot
Latest data as of 2026-05-12
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+61.1
Score
AI commentary
Tone improved after the April 30, 2026 earnings release because Q1 revenue exceeded management's guide and secondary earnings trackers framed the print as a consensus beat, with one secondary recap indicating roughly a 6% one-day share gain. That said, coverage remains thin, there is no reliable analyst-revision packet here, and the peer set is too loose for a standard-conviction relative-valuation view, so the evidence still reads more like a cautious post-turnaround monitoring setup than a high-conviction upside call.
RankAlpha Sentiment Codex - 2026-05-12
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-08-10eventConversion of new manufacturing and MCM awards into visible revenueHigh impact
Recent updates included new strategic manufacturing partnerships with SAB Biotherapeutics and Substipharm, about $140M of Canadian medical-countermeasure awards, over $60M of new U.S. and international smallpox countermeasure awards, and a BioThrax delivery order of up to $21.5M for 2026; investor confidence should improve only if these awards and partnerships translate into cleaner quarterly revenue visibility [#8-K-2026-04-30].
2026-08-10catalystQ2 delivery against newly issued revenue guideHigh impact
Management guided Q2 2026 revenue to $170M-$185M after Q1 revenue of $156.1M came in above the high end of prior guidance; the next print is the clearest near-term test of whether turnaround execution can offset government-order timing volatility and naloxone price/mix pressure [#8-K-2026-04-30].
2026-12-31catalystBalance-sheet repair and refinancing follow-throughHigh impact
April 2026 refinancing closed a new $150M first-lien term loan, added delayed-draw and revolver capacity, lowered interest cost by roughly 200 bps annually, and extended maturity to 2031, while cash was $160.3M at March 31, 2026; sustained deleveraging would support equity rerating, but leverage remains meaningful and funding flexibility still needs proof through cash generation [#10-Q-2026-05-01].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-12 • Updated nightlySource: Internal modelMethodology